• Globe Newswire

Lira Clinical Announces New REGEN Line — A First-of-Its-Kind Breakthrough in Regenerative Skincare

Globenewswire -

• Globe Newswire

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Globenewswire -

• Globe Newswire

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

Globenewswire -

• Globe Newswire

Quantexa Named as a Category Leader in Chartis Research’s 2025 AML Transaction Monitoring and KYC Solutions Reports

Globenewswire -

• Globe Newswire

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Globenewswire -

• Globe Newswire

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Globenewswire -

• Globe Newswire

Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies